Home > News Center
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
Prevenar got approval for use in adolescents in EU
Jan. 3, 2013
Pfizer's pneumococcal conjugate vaccine, Prevenar 13, was approved for use in children aged from 6 to 17 in EU. The vaccine has already been approved in 120 countries for use in children less than 6. Analysts expect the vaccine sale to reach $6.75 billion by 2016.
Gates Foundation promotes oral cholera vaccine
Jan. 6, 2013
The Bill & Melinda Gates Foundation gave $5 million to the Johns Hopkins Bloomberg School of Public Health to support the Delivering Oral Vaccine Effectively (DOVE) program to promote use of oral cholera vaccine worldwide. Currently, two oral cholera vaccines are available, i.e. Crucell's Dukoral and Shantha Biotechnics' Shanchol, which are 70% effective and cost merely $1.85 per dose. But they are not widely used yet.
Chinese ministries jointly promoting the implementation of new GMP
Jan. 10, 2013
The notice on accelerating the implementation of newly revised GMP and promoting pharmaceutical industry upgrading was recently jointly issued by the State Food and Drug Administration, National Development and Reform Commission, Ministry of Industry and Information Technology and Ministry of Health in China. Under the original standard and schedule, the four government departments advanced incentives in merger and reorganization, certification and inspection, examination and approval, contract manufacturing, price adjustment, bid procurement and technical improvement to encourage and guide drug manufacturing enterprises to meet the requirements of the new version GMP.
Bexsero showed positive results in infants
Jan. 13, 2013
Novartis's meningococcus B vaccine, Bexsero, which was previously backed up by European Medicine Agency committee, showed positive results in a clinical study that involved 3630 researchers and infants aged 2 months older. A three dose primary administration plus a fourth dose administered 12 months later could provide broad protection to infants.
Novartis's meningitis B vaccine Bexsero got EU approval
Jan. 18, 2013
Novartis's meningitis B vaccine, Bexsero, has got EU approval to become the first marketed vaccine to combat meningococcus B bacteria. Analysts estimate that European Bexsero market will be between $600 million and $700 million.
WHO warns of Dengue
Jan. 22, 2013
Dengue is now present in more than 125 countries. In 2012, dengue ranked as the fastest spreading vector-borne viral disease with an epidemic potential in the world, representing a 30-fold increase over the past 50 years, stated WHO last week.
There is no specific treatment so far. The most advanced dengue vaccine developed by Sanofi is only 30% effective.
New technology to deliver vaccines
Jan. 28, 2013
An Australian engineer is trying to transform vaccine delivery from needle and syringe system to a novel needleless "nanopatch". The nanopatch is designed to place a tiny amount of vaccine just under the skin without the need for a needle jab. Tests have shown it can generate same immune response with only a fraction of the dose needed in a conventional vaccine. Also it does not need cold-chain or trained staff to deliver it.
BravoBio won the 5th BioSpectrum Asia-Pacific Emerging Company of the Year Award 2013
Feb. 1, 2013
BravoBio has bagged the 5th BioSpectrum Asia-Pacific Emerging Company of the Year Award 2013. Every year, BioSpectrum recognizes 6-10 companies in the Asia Pacific region with this Award. A profile of the award winner will appear in the March 2013 edition of BioSpectrum Asia.
BravoBio team visited Turkey
Feb. 5, 2013
BravoBio team visited one of the largest pharma companies in Turkey. The parties talked about multi-lateral collaboration in the future. The host raised Chinese national flag for the guests.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next